StocksMedium•28 September 2026•
1 min read
Inventiva Beats Q2 Earnings Estimates as Investors Weigh Clinical Trial Risks
Key Facts
1Inventiva reported an adjusted EPS of negative $0.3818, beating the expected negative $0.5374.
2The company's Q2 revenue reached $6.4 million, surpassing the $6.0 million forecast.
3Investors are awaiting Phase III NATiV3 trial data for lanifibranor expected in Q4 2026.
Inventiva reported an adjusted EPS of negative $0.3818 for the second quarter of 2026, beating analyst expectations of a negative $0.5374 loss. Investing.com reported that the company's revenue reached $6.4 million, surpassing the forecasted $6.0 million.
IVA closed at $3.37 on September 25, 2026, with the stock trading between a low of $3.16 and a high of $3.43 during that session. Investors are now focused on the Phase III NATiV3 trial data for lanifibranor expected in the fourth quarter of 2026, maintaining a cautious outlook despite the quarterly financial outperformance.